This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Gilead (GILD) Exercises Option to License Nurix's Candidate
by Zacks Equity Research
Gilead (GILD) exercises an option under its collaboration agreement with Nurix to license the latter???s investigational targeted protein degrader molecule NX 0479.
NVOPositive Net Change GILDNegative Net Change LGNDPositive Net Change NRIXNegative Net Change
biotechnology biotechs pharmaceuticals
Here's Why You Should Add CRISPR Stock to Your Portfolio
by Zacks Equity Research
CRISPR Therapeutics (CRSP), a top-ranked stock at present, is developing its lead pipeline candidate to treat TDT and SCD.
VRTXPositive Net Change EDITNegative Net Change CRSPNegative Net Change JSPRNegative Net Change
biotechnology crispr gene-editing medical
Axsome (AXSM) Stock Up 17% in Six Months: Here's Why
by Zacks Equity Research
Axsome's (AXSM) shares have surged 17.2% in the past six months, owing to the launch of its first product, Auvelity, in October last year. Also, the addition of Sunosi boosts its top line.
AXSMNegative Net Change KALAPositive Net Change CERTPositive Net Change JSPRNegative Net Change
biotechnology medical
Incyte (INCY) Vitiligo Drug Povorcitinib Positive in Phase II
by Zacks Equity Research
Incyte (INCY) announces positive data on povorcitinib and Opzelura for the treatment of nonsegmental vitiligo.
NVSPositive Net Change NVOPositive Net Change INCYPositive Net Change LGNDPositive Net Change
biotechnology pharmaceuticals
Buy 5 High ROE Stocks as Markets Brace for 25 Bps Rate Hike
by Supriyo Bose
AutoNation (AN), Atkore (ATKR), Valero (VLO), Hologic (HOLX) and Ryder (R) are some of the stocks with high ROE to profit from as markets brace for another rate hike.
RNegative Net Change VLOPositive Net Change ANNegative Net Change HOLXPositive Net Change ATKRNegative Net Change
auto-tires-trucks biofuels biotechnology industrial-products
Palo Alto Networks (PANW)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
PANWNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Sarepta (SRPT) Stock Down, FDA to Hold Panel Meet for SRP-9001
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) shares plunged almost 20% as the FDA decides to hold an advisory meeting for the BLA of its lead gene therapy candidate SRP-9001.
SRPTNegative Net Change KALAPositive Net Change CERTPositive Net Change JSPRNegative Net Change
biotechnology gene-therapy medical
Regeneron (REGN) Gains 9.3% in a Year: Will the Uptrend Last?
by Zacks Equity Research
Regeneron (REGN) has had a good run in the past 12 months and the momentum should continue in 2023 on the back of growth in Dupixent, as Eylea faces challenges.
REGNPositive Net Change SNYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs pharmaceuticals
Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain?
by Zacks Equity Research
Gilead (GILD) gains 34% in the past 12 months as its HIV business and rapidly growing oncology business maintain momentum despite volatility.
GSKPositive Net Change NVOPositive Net Change GILDNegative Net Change LGNDPositive Net Change
biotechnology biotechs pharmaceuticals
Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate
by Zacks Equity Research
Prelude Therapeutics (PRLD) and BeiGene collaborate on clinical trials to evaluate PRT2527 with zanubrutinib for treating hematologic cancer patients.
BGNEPositive Net Change CRSPNegative Net Change KALAPositive Net Change PRLDNegative Net Change
biotechnology medical
Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More
by Zacks Equity Research
Acadia's (ACAD) pipeline and regulatory updates, and Seagen's (SGEN) acquisition news are the key highlights from the biotech sector during the past week.
GSKPositive Net Change SGENPositive Net Change ACADNegative Net Change MRSNNegative Net Change ARDSNo Net Change
biotechnology biotechs pharmaceuticals
SOPHiA GENETICS SA (SOPH) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
SOPHPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Alkermes (ALKS) Stock Up 15% in Six Months: Here's Why
by Zacks Equity Research
Alkermes shares have surged in the past six months, owing to strong sales performance of its new drug Lybalvi and its decision to separate the oncology unit.
ALKSPositive Net Change HZNPPositive Net Change CRSPNegative Net Change KALAPositive Net Change
biotechnology medical
Agilent (A) Boosts Digital Pathology Reach With Hamamatsu Deal
by Zacks Equity Research
Agilent Technologies (A) signs a digital pathology solutions distribution agreement with Hamamatsu in a bid to strengthen its DGG segment.
ADINegative Net Change CRMPositive Net Change APositive Net Change ANETNegative Net Change
biotechnology tech-stocks
Aridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals
by Zacks Equity Research
Aridis Pharmaceuticals (ADRS) meets primary and secondary endpoints in a phase IIa study on AR-501 for treating cystic fibrosis.
CRSPNegative Net Change KALAPositive Net Change ARDSNo Net Change ALLONegative Net Change
biotechnology medical pharmaceuticals
Should You Buy Telesis Bio (TBIO) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
TBIONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Company News for Mar 14, 2023
by Zacks Equity Research
Companies In The News Are: SGEN, PFE, PODD, SIVB, ILMN, PNC.
PNCPositive Net Change PFEPositive Net Change ILMNPositive Net Change PODDPositive Net Change SIVBPositive Net Change SGENPositive Net Change
biotechnology finance medical pharmaceuticals
Reata (RETA) Stock Doubles This Year on Skyclarys FDA Nod
by Zacks Equity Research
Reata Pharmaceuticals (RETA) stock more than doubles this year, owing to approval for its rare disease drug.
RETAPositive Net Change CRSPNegative Net Change KALAPositive Net Change ALLONegative Net Change
biotechnology medical
Agilent (A) Boosts Biopharma Solutions Offerings With e-Msion
by Zacks Equity Research
Agilent Technologies (A) announces the acquisition of e-Msion, to bolster its Life Sciences & Applied Markets Group segment.
ADINegative Net Change CRMPositive Net Change APositive Net Change ANETNegative Net Change
biotechnology tech-stocks
Intercept (ICPT) Stock Down on FDA Committee Update on NDA
by Zacks Equity Research
Intercept (ICPT) declines on news of a GIDAC meeting to discuss the NDA for the OCA for NASH in May.
ICPTPositive Net Change VKTXNegative Net Change MDGLNegative Net Change
biotechnology biotechs pharmaceuticals
Amphastar Pharmaceuticals (AMPH)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
AMPHPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Roche (RHHBY) Polivy Combo Backed by FDA Advisory Committee
by Zacks Equity Research
Roche (RHHBY) gets majority votes from the FDA's Advisory Committee for Polivy combination for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL).
RHHBYNegative Net Change NVOPositive Net Change ALLONegative Net Change
biotechnology pharmaceuticals
Heres Why Intercept (ICPT) Stock is Up 28.7% in 3 Months
by Zacks Equity Research
Intercept (ICPT) gains 28.7% in the past 3 months on NDA's acceptance for NASH treatment and Ocaliva's performance.
ICPTPositive Net Change VKTXNegative Net Change MDGLNegative Net Change
biotechnology biotechs pharmaceuticals
Vertex (VRTX) to Begin Clinical Study on Type I Diabetes Drug
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) receives FDA clearance to begin clinical development of VX-264, which has the potential to treat type I diabetes.
VRTXPositive Net Change CRSPNegative Net Change KALAPositive Net Change ALLONegative Net Change
biotechnology cell-therapy medical
Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More
by Zacks Equity Research
Pipeline and regulatory updates from Protagonist (PTGX) and BioMarin (BMRN) are the key highlights from the biotech sector during the past week.
BMRNPositive Net Change INCYPositive Net Change EXELNegative Net Change PTGXPositive Net Change BBIONegative Net Change
biotechnology biotechs pharmaceuticals